2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

2:30PM-4:00PM: Abstract Number: 851

Association Between Bone Marrow Edema and Structural Progression in the Same Quadrant in Axial Spondyloarthritis – 5-year Data from the DESIR Cohort

3S083: Spondyloarthritis Including Psoriatic Arthritis – Clinical I: Imaging in Axial Spondyloarthritis & Psoriatic Arthritis (851–856)

2:30PM-4:00PM: Abstract Number: 864

Change in Scleroderma Skin Histology Correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in Patients with Early, Diffuse Cutaneous Systemic Sclerosis

3S084: Systemic Sclerosis & Related Disorder – Clinical I: Therapeutics & Outcomes (863–868)

2:30PM-4:00PM: Abstract Number: 822

Cigarette Smoking Is a Risk Factor for ANCA-Associated Vasculitis

3S074: Epidemiology & Public Health I: Risk Factors & Outcomes for Rheumatic Diseases (821–826)

2:30PM-4:00PM: Abstract Number: 869

Clinical Manifestations of Patients with Eosinophilic Granulomatosis with Polyangiitis in a Large North American Cohort

3S085: Vasculitis – ANCA-Associated I (869–874)

2:30PM-4:00PM: Abstract Number: 874

Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features

3S085: Vasculitis – ANCA-Associated I (869–874)

2:30PM-4:00PM: Abstract Number: 845

Comparison of Rituximab-Associated Hypogammaglobulinemia Rates in Patients with Systemic Rheumatologic Conditions

3S080: RA – Treatments I: Safety and Outcomes (845–850)

2:30PM-4:00PM: Abstract Number: 861

Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE

3S081: SLE – Clinical I: Clinical Trials (857–862)

2:30PM-4:00PM: Abstract Number: 832

Diagnosis of Fibromyalgia: Comparison of AAPT and ACR Criteria

3S075: Fibromyalgia & Other Clinical Pain Syndromes (827–832)

2:30PM-4:00PM: Abstract Number: 829

Dietary Intake Does Not Explain Microbiome Alterations or Symptom Severity in Fibromyalgia

3S075: Fibromyalgia & Other Clinical Pain Syndromes (827–832)

2:30PM-4:00PM: Abstract Number: 839

Disease Activity, Cytokine Profiles, and the Risk of Incident Diabetes in Rheumatoid Arthritis

3S078: RA – Diagnosis, Manifestations, & Outcomes I: Pulmonary & Other Comorbidities (839–844)

2:30PM-4:00PM: Abstract Number: 820

Diurnal Stability of Transcriptional Profiles in Rheumatoid Arthritis

3S079: RA – Etiology & Pathogenesis I (815–820)

2:30PM-4:00PM: Abstract Number: 854

Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort

3S083: Spondyloarthritis Including Psoriatic Arthritis – Clinical I: Imaging in Axial Spondyloarthritis & Psoriatic Arthritis (851–856)

2:30PM-4:00PM: Abstract Number: 837

Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network

3S076: Patient Outcomes, Preferences, & Attitudes I: Patient Reported Outcomes (833–838)

2:30PM-4:00PM: Abstract Number: 833

Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial

3S076: Patient Outcomes, Preferences, & Attitudes I: Patient Reported Outcomes (833–838)

2:30PM-4:00PM: Abstract Number: 875

Effect of the Dr. Bart Application on Healthcare Use and Clinical Outcomes in People with Osteoarthritis of the Knee And/or Hip in the Netherlands; A Randomized Controlled Trial

3S092: New Approaches to Old Diseases (875–879)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].